| Company Name: |
Wuhan Chemstan Biotechnology Co., Ltd.
|
| Tel: |
027-65317797 15926423062 |
| Email: |
422450190@qq.com |
| Products Intro: |
Product Name:Otlertuzumab
Purity:>95%;1mg/ml Package:200ug;500ug;1mg
|
| Company Name: |
Biolab Reagents
|
| Tel: |
027-65279366 18108604356 |
| Email: |
products@biolabreagent.com |
| Products Intro: |
Product Name:Otlertuzumab
CAS:1372645-37-8
Purity:PAGE:>95% Package:100ug;1mg
|
| Company Name: |
Shanghai Yifei Biotechnology Co. , Ltd.
|
| Tel: |
021-65675885 18964387627 |
| Email: |
customer_service@efebio.com |
| Products Intro: |
Product Name:Otlertuzumab
CAS:1372645-37-8
Purity:95% Package:1mg;5mg
|
| Company Name: |
Changsha Fuzhen Biotechnology Co.，LTD
|
| Tel: |
0731-13823398 15111215862 |
| Email: |
313359644@qq.com |
| Products Intro: |
Product Name:Otlertuzumab
CAS:1372645-37-8
Purity:95.00% Package:100ug 500ug 1mg 5mg
|
|
| | Otlertuzumab Basic information |
| Product Name: | Otlertuzumab | | Synonyms: | Otlertuzumab;Research Grade Otlertuzumab(DHC85103);Research Grade Otlertuzumab | | CAS: | 1372645-37-8 | | MF: | | | MW: | 0 | | EINECS: | | | Product Categories: | | | Mol File: | Mol File | ![Otlertuzumab Structure]() |
| | Otlertuzumab Chemical Properties |
| form | Liquid | | color | Colorless to light yellow |
| | Otlertuzumab Usage And Synthesis |
| Uses | Otlertuzumab (TRU-016) is a humanized anti-CD37 monoclonal antibody that can be used for cancer research[1]. | | in vivo | Otlertuzumab (TRU-016) in combination with Bendamustine.html" class="link-product" target="_blank">Bendamustine (HY-13567) displays greater anti-tumor activity than either agent alone against a follicular lymphoma tumor model in SCID mice[2].
Otlertuzumab shows significant antitumor activity in mice bearing Ramos or Daudi tumor xenografts[3]. | | Enzyme inhibitor | This intravenously administered anti-CD37 IgG fusion protein (MW = 107.5 kDa; CAS 1372645-37-8), also known by its code name TRU-016, is intended for the treatment of B-cell malignancies, including chronic lymphocytic leukemia (CLL) and non-Hodgkin's lymphoma (NHL), as well as for autoimmune and inflammatory diseases. Otlertuzumab was created by humanizing SMIP-016, a mouse/human chimeric protein that demonstrates antitumor activity against lymphoid malignancies in preclinical studies, including in human B-cell tumor mouse xenograft models. TRU-016 demonstrates synergistic or additive activity in NHL cells in combination with rituximab, rapamycin, doxorubicin and bendamustine. In a phase I/II clinical trial in refractory or relapsed patients with CLL or small lymphocytic lymphoma, Otlertuzumab is well tolerated, with clinical benefit and a reduced absolute lymphocyte count observed in all cohorts dosed at > 0.1 mg/kg. TRU-016 is a promising therapeutic agent for patients with B-cell lymphoid malignancies, especially patients refractory to standard treatment. | | References | [1] Byrd JC, et al. A phase 1 study evaluating the safety and tolerability of otlertuzumab, an anti-CD37 mono-specific ADAPTIR therapeutic protein in chronic lymphocytic leukemia. Blood. 2014 Feb 27;123(9):1302-8. DOI:10.1182/blood-2013-07-512137
[2] Baum P R, et al. Evaluation of the effect of TRU-016, an anti-CD37 directed SMIP in combination with other therapeutic drugs in models of non-Hodgkin's lymphoma. Journal of Clinical Oncology, 2009, 27(15_suppl): 8571-8571.
[3] Cerveny C G, et al. In vitro and in vivo anti-B cell lymphoma activities of TRU-016. Journal of Clinical Oncology, 2008, 26(15_suppl): 3074-3074. |
| | Otlertuzumab Preparation Products And Raw materials |
|